Related Experiment Video
Updated: Jul 14, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Relationship between frontal N-acetylaspartate and cognitive deficits in first-episode schizophrenia
Beata Galińska1, Agata Szulc, Eugeniusz Tarasów
1Department of Psychiatry, Medical University of Białystok, Białystok, Poland. begal@poczta.onet.pl <begal@poczta.onet.pl>
Background:
The aim of this study was to evaluate the relationship between N-acetylaspartate (NAA) levels in selected brain regions and cognitive performance in patients with first-episode schizophrenia.
Material/Methods:
Thirty patients (20 male, 10 female; mean age: 22.5 years) with the diagnosis of first-episode schizophrenia and 19 comparable healthy controls were studied. The Wisconsin Card Sorting Test (WCST) was used to assess cognitive functions. MR imaging and MR spectroscopy examinations were performed on a 1.5 T scanner. Voxels of 8 cm3 were positioned in the left frontal lobe, left temporal lobe, and left thalamus. The ratio of NAA to creatine and the ratio of NAA to unsuppressed water signal were analyzed.
Results:
Patients performed significantly worse than controls on measures of the WCST. In the patient group, NAA levels in the frontal lobe were significantly related to poorer WCST performance.
Conclusions:
Cognitive impairment related to dysfunction of the prefrontal cortex in first-episode schizophrenia is associated with NAA level in the frontal lobe.
More Related Videos
Related Concept Videos
Alzheimer Disease l: Introduction
Negative and Cognitive Symptoms of Schizophrenia
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Alzheimer's Disease: Treatment

